Compare RGR & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RGR | MLYS |
|---|---|---|
| Founded | 1949 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Ordnance And Accessories | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 601.9M | 2.5B |
| IPO Year | 1994 | 2023 |
| Metric | RGR | MLYS |
|---|---|---|
| Price | $38.23 | $30.92 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 7 |
| Target Price | $43.00 | ★ $48.67 |
| AVG Volume (30 Days) | 104.1K | ★ 929.4K |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.07% | N/A |
| EPS Growth | N/A | ★ 37.43 |
| EPS | ★ 0.44 | N/A |
| Revenue | ★ $546,057,000.00 | N/A |
| Revenue This Year | $2.38 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $86.57 | ★ N/A |
| Revenue Growth | ★ 1.94 | N/A |
| 52 Week Low | $28.33 | $22.30 |
| 52 Week High | $48.21 | $47.65 |
| Indicator | RGR | MLYS |
|---|---|---|
| Relative Strength Index (RSI) | 51.71 | 68.09 |
| Support Level | $36.73 | $25.34 |
| Resistance Level | $38.99 | $31.26 |
| Average True Range (ATR) | 0.94 | 1.32 |
| MACD | 0.04 | 0.57 |
| Stochastic Oscillator | 52.74 | 87.35 |
Sturm Ruger & Co Inc and its subsidiary are principally engaged in the design, manufacture, and sale of firearms to domestic customers. The company's design and manufacturing operations are in the United States, and almost all product content is domestic. The company has two reportable operating segments: firearms and castings. The firearms segment manufactures and sells rifles, pistols, and revolvers principally to a number of federally-licensed, independent wholesale distributors located in the United States. The castings segment manufactures and sells steel investment castings and metal injection molding parts. It generates maximum income from the sale of Firearms.
Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.